ProShare Advisors’s Day One Biopharmaceuticals DAWN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-33,247
| Closed | -$713K | – | 1941 |
|
|
2026
Q1 | $713K | Buy |
33,247
+14,352
| +76% | +$202K | ﹤0.01% | 900 |
|
|
2025
Q4 | $176K | Buy |
18,895
+2,939
| +18% | +$24.6K | ﹤0.01% | 1758 |
|
|
2025
Q3 | $112K | Sell |
15,956
-2,589
| -14% | -$17.8K | ﹤0.01% | 1824 |
|
|
2025
Q2 | $121K | Buy |
18,545
+2,121
| +13% | +$14.6K | ﹤0.01% | 1840 |
|
|
2025
Q1 | $130K | Sell |
16,424
-2,970
| -15% | -$32K | ﹤0.01% | 1781 |
|
|
2024
Q4 | $246K | Buy |
19,394
+3,687
| +23% | +$51.3K | ﹤0.01% | 1770 |
|
|
2024
Q3 | $219K | Buy |
15,707
+1,920
| +14% | +$27.4K | ﹤0.01% | 1673 |
|
|
2024
Q2 | $190K | Sell |
13,787
-3,592
| -21% | -$52.6K | ﹤0.01% | 1542 |
|
|
2024
Q1 | $287K | Buy |
17,379
+1,447
| +9% | +$21.7K | ﹤0.01% | 1451 |
|
|
2023
Q4 | $233K | Buy |
15,932
+2,108
| +15% | +$25.6K | ﹤0.01% | 1555 |
|
|
2023
Q3 | $170K | Buy |
13,824
+2,660
| +24% | +$34.7K | ﹤0.01% | 1515 |
|
|
2023
Q2 | $133K | Buy |
+11,164
| New | +$146K | ﹤0.01% | 1643 |
|
|
2023
Q1 | – | Sell |
-9,645
| Closed | -$208K | – | 1819 |
|
|
2022
Q4 | $208K | Buy |
+9,645
| New | +$198K | ﹤0.01% | 1468 |
|
|
2022
Q2 | – | Sell |
-10,675
| Closed | -$106K | – | 1872 |
|
|
2022
Q1 | $106K | Sell |
10,675
-452
| -4% | -$5.97K | ﹤0.01% | 2016 |
|
|
2021
Q4 | $188K | Buy |
+11,127
| New | +$229K | ﹤0.01% | 2052 |
|
Other funds holding DAWN
ProShare Advisors's DAWN Position: Q2 2026 in Review
ProShare Advisors sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 33,247 shares — an estimated $713K sold.
ProShare Advisors first reported a position in DAWN in Q4 2021 and held it in 15 quarters. The position peaked at $713K in Q1 2026. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.
- ProShare Advisors reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
- ProShare Advisors sold 33,247 Day One Biopharmaceuticals shares in Q2 2026, an estimated $713K.
- ProShare Advisors first reported a position in Day One Biopharmaceuticals in Q4 2021 and held it in 15 quarters.
- ProShare Advisors's Day One Biopharmaceuticals position peaked at $713K in Q1 2026.
- 1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.
Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.